Uveal melanoma

07/01/2013 - "This form of therapy is effective for a wider range of uveal melanoma than any other modality, providing exceptionally-high rates of local tumor control. "
03/01/2009 - "Conservative treatments for uveal melanoma, especially brachitherapy, are safe and effective in relation to tumor control and rate of secondary effects."
04/01/2012 - "With improved understanding of genetic prognostic factors of uveal melanoma, ophthalmic FNAB is gaining popularity for prognostic purposes in combination with eye conserving treatment of the primary tumor. "
11/01/2008 - "SCID mice xenografted with uveal melanoma cells were used to determine anti-tumor efficacy of oral PPP in vivo. "
01/01/2014 - "Prospective non-randomized IRB-approved single-center longitudinal clinical study of 159 patients with posterior uveal melanoma sampled by FNAB in at least two tumor sites between 09/2007 and 12/2010. "

05/01/2009 - "Regular screening for hepatic metastasis in patients with uveal melanoma may be beneficial in identifying those who would benefit from HACE."
06/01/2010 - "TACE is well tolerated and effective in pretreated patients with liver metastases from uveal melanoma. "
02/01/2011 - "The purpose of this study was to assess the safety and efficacy of radioembolization in the management of hepatic metastasis of uveal melanoma after failure of immunoembolization or chemoembolization. "
04/01/2015 - "TACE seems to be a tolerable regimen that confers an improvement in the survival of uveal melanoma patients with liver metastases. "
07/01/2010 - "Remission of extensive intrahepatic metastasis by C-arm computed tomography guided chemoembolization in uveal melanoma."

03/01/2007 - "Results demonstrated that MC1R is expressed by uveal melanoma to a significantly greater extent than other melanoma markers. "
06/15/1989 - "Although the observed prevalence of cutaneous melanoma was not significantly greater than expected, three cases with both primary cutaneous and uveal melanoma were reported. "
05/01/1997 - "Posterior uveal melanomas have nonrandom alterations affecting chromosomes 3, 6, and 8. Loss of chromosome 3 in uveal melanoma has been shown to act as a predictor of disease-free and overall survival. "
01/01/2014 - "Uveal melanomas treated by primary enucleation in Chinese patients underwent a mutation analysis of GNAQ and GNA11 with sequencing of exon 5 and exon 4. The study included 50 patients with uveal melanoma and with a mean age of 47.6±13.0 years. "
10/01/2013 - "In this study, to compare response rates of systemic treatment for MUM we searched Pubmed/Web of Knowledge databases and ASCO website (1980-2013) for "metastatic/uveal/melanoma" and "melanoma/eye." Forty studies (one case series, three phase I, five pilot, 22 nonrandomized, and two randomized phase II, one randomized phase III study, data of three expanded access programs, three retrospective studies) with 841 evaluable patients were included in the numeric outcome analysis. "

05/01/2015 - "To determine the frequency of early subclinical macular edema in eyes with uveal melanoma and its association with future cystoid macular edema (CME). "
05/01/2015 - "Early subclinical macular edema in eyes with uveal melanoma: association with future cystoid macular edema."
09/01/2012 - "Cystoid macular edema is caused by many conditions, but it is rarely associated with uveal melanoma. "
03/01/2014 - "We studied 36 patients with macular edema after plaque radiotherapy of uveal melanoma in this noncomparative, interventional case series. "
02/01/2008 - "To evaluate the time of onset and risk factors for the development of macular edema following plaque radiotherapy for uveal melanoma, using optical coherence tomography (OCT). "

01/01/2014 - "Finally, we showed in a multicenter, prospective study that our GEP assay is highly accurate for predicting which patients will develop metastatic disease, and it was significantly superior to the previous gold standard, chromosome 3 testing for monosomy 3. This is the only prognostic test in uveal melanoma ever to undergo such extensive validation, and it is currently being used in a commercial format under the trade name DecisionDx-UM in over 100 centers in the USA and Canada. "
03/01/2013 - "In the present study, whole-genome microarrays were used to interrogate four clinically well-defined subgroups of uveal melanoma: i) disomy 3 uveal melanoma with long-term survival; ii) metastasizing monosomy 3 uveal melanoma; iii) metastasizing disomy 3 uveal melanoma; and iv) monosomy 3 uveal melanoma with long-term survival. "
01/01/2007 - "To study the distribution of monosomy 3 in primary uveal melanoma by fluorescence in situ hybridization (FISH). "
09/01/2006 - "This study confirms previous results on the prognostic factors of uveal melanoma and on the value of monosomy 3. The increasingly precise identification of a group of high-risk patients should allow us to propose adjuvant therapy and to adapt follow-up."
04/01/1998 - "This study did not detect the presence of cryptic deletions but revealed instead complete chromosomal homozygosity or functional monosomy, which probably occurred by loss and then duplication of the remaining chromosome 3. The demonstration of acquired isodisomy (functional monosomy) in a subset of UM increases the percentage of cases with monosomy 3 and provides further evidence for a central role of chromosome 3 loss in the molecular pathogenesis of uveal melanoma."